











Manuscript version: Author’s Accepted Manuscript 
The version presented in WRAP is the author’s accepted manuscript and may differ from the 
published version or Version of Record. 
 
Persistent WRAP URL: 
http://wrap.warwick.ac.uk/144392                    
 
How to cite: 
Please refer to published version for the most recent bibliographic citation information.  
If a published version is known of, the repository item page linked to above, will contain 
details on accessing it. 
 
Copyright and reuse: 
The Warwick Research Archive Portal (WRAP) makes this work by researchers of the 
University of Warwick available open access under the following conditions.  
 
Copyright © and all moral rights to the version of the paper presented here belong to the 
individual author(s) and/or other copyright owners. To the extent reasonable and 
practicable the material made available in WRAP has been checked for eligibility before 
being made available. 
 
Copies of full items can be used for personal research or study, educational, or not-for-profit 
purposes without prior permission or charge. Provided that the authors, title and full 
bibliographic details are credited, a hyperlink and/or URL is given for the original metadata 
page and the content is not changed in any way. 
 
Publisher’s statement: 
Please refer to the repository item page, publisher’s statement section, for further 
information. 
 
For more information, please contact the WRAP Team at: wrap@warwick.ac.uk. 
 
Navigating the Pain and Suicide Conundrum  
 
Martin D. Cheatle*, Simmie Foster # and Nicole Tang! 
 
*Perelman School of Medicine at the University of Pennsylvania, Philadelphia PA, USA 
# Harvard Medical School. Boston MA, USA 
!University of  Warwick, Coventry, UK 
 
 
Corresponding Author:   
Martin D. Cheatle, PhD 
Associate Professor 
Center for Studies of Addiction 
Perelman School of Medicine 
University of Pennsylvania 
3535 Market Street, 4th floor 
Philadelphia, Pa  19104 
Phone:  215-746-7365 




MDC would like to acknowledge the support from Grant 1R01DA032776-01 from the 
National Institute on Drug Abuse, National Institutes of Health in the writing of this 
manuscript. 
 
Key Words:  




Individuals that suffer from chronic pain typically experience a number of medical, social 
and psychiatric co-morbidities that greatly affect their quality of life. Patients with pain 
often experience depression, anxiety, and the prevalence of suicidal ideation and 
behavior is not inconsequential in this patient population. Suicide in patients with 
chronic pain has been a silent epidemic but there is an emerging literature in this area. 
This chapter will provide a review of the prevalence of suicide in both patients with pain 
and those with pain and substance use disorders, risk factors for suicide, possible 
















 There has been a great deal of scholarly activity devoted to the burgeoning rate of 
opioid misuse/abuse and opioid-related fatalities, particularly in the United States. 
However, this has overshadowed the silent epidemic of suicidal ideation (SI) and suicidal 
behavior (SB). Suicide has become a global problem. The World Health Organization 
published an executive summary, “Preventing Suicide, A Global Imperative”. 1 In this 
summary, there were some alarming facts: every 40 seconds someone in the world dies 
of suicide; an estimated 804,000 suicide deaths occurred worldwide in 2012; the annual 
global suicide rate was 11.4/100,000 population (15.0 male and 8.0 female); and in the 
age group of 15-29 it is the second leading cause of death. Suicide constitutes 54% of 
the 1.5 million violent deaths per year globally. Over 75% of suicides occur in low and 
middle-income families, and all of these numbers continue to grow annually.  
Pain and Suicide 
 A robust literature underscores that there is a high prevalence of SI and SB in 
patients with pain, ranging anywhere from 18%-50%. 2-7 A systematic review by Tang and 
Crane5 revealed that the risk of successful suicide was doubled in patients with chronic 
pain as compared to non-pain controls. Ilgen et al2 discovered in a large cohort from the 
United States Veterans Affairs’ database (n=260,254) that veterans experiencing severe 
pain were more likely to end their life by suicide than veterans with no, mild, or moderate 
pain).  Cheatle et al3 evaluated 466 patients with chronic nonmalignant pain treated in a 
behaviorally based pain program. Results revealed a high rate of SI (26%) and a logistic 
regression revealed that history of sexual abuse, family history of depression and being 
socially withdrawn were predictive of SI.   
Suicidal Ideation and Behavior and Substance Use Disorder 
 Compared to the general population, individuals with an alcohol use disorder are 
almost 10 times more likely to die by suicide and those who inject drugs are approximately 
14 times more likely to commit suicide.8 These individuals tend to have multiple risk 
factors for SB including having depressive symptoms and enduring a significant number 
of severe stressors such as loss of relationships, jobs, health and financial problems.   
Patients with co-occurring pain and substance use disorder (SUD) are particularly at high 
risk for attempting and ending their lives by suicide.  
Pain and Suicidal Ideation and Behavior: Risk Factors 
 There are general, non-pain specific risk factors and pain-specific risk factors for 
suicidality. General, non-pain specific risk factors include gender (female); age (> 45 
years old); having co-occurring mental disorders (especially depression and SUD); acute 
losses and stressors (relationships, job, finances); enduring chronic medical illnesses; 
experiencing conflict, disaster, discrimination; past psychiatric hospitalizations; frequency 
of SI; severity of psychiatric disorder; poor social support and the strongest predictor of 
suicide is a previous suicide attempt. 1,9  While patients with pain commonly have a 
number of these risk factors, 10 pain specific risk factors include pain duration, pain 
intensity, sleep disturbance, catastrophizing, mental defeat and opioid dosing. General 
and pain-specific risk factors for SI and SB are outlined in Table 1.  
Pain Duration and Intensity 
 There is generally convincing evidence that pain intensity 5,6  and pain duration5 
are predictive of SI and SB. In a large cohort study, Ilgen et al6 analyzed data from the  
Veteran’s Affairs’ medical records database and the National Death Index (n=260,254) 
evaluating the association between self-assessed pain severity and SB in veterans. They 
discovered after controlling for demographic and psychiatric factors that veterans with 
severe pain were more likely to die by suicide than ones with mild or moderate pain. 
Sleep Disturbance 
 Sleep disturbance is very common in patients with chronic pain with the prevalence 
ranging from 50 to 80%11, 12,14 and has been postulated as a potential mediator of suicidal 
ideation in this patient population. Racine et al 13 examined data of 88 patients with chronic 
pain who completed a number of self-administered questionnaires at intake to three pain 
clinics in Canada. They discovered that 24 % of these patients endorsed experiencing SI. 
Poor sleep quality was the only significant physical variable predictor of SI. There is also 
persuasive evidence that pain and sleep are bidirectional (pain leading to poorer sleep 
quality and sleep deprivation causing increased pain) which potentially could 
synergistically increase the risk of SI and SB.  Although sleep disturbance is common in 
patients with pain it is often not evaluated or effectively treated.14 
Opioid Dosing  
 Ilgen et al15 performed a retrospective data analysis on the risk of suicide by 
different opioid doses in Veterans with chronic nonmalignant pain. After controlling for 
demographic and other clinical features (depression, PTSD etc) results indicated that 
higher opioid doses were associated with increased risk of suicide mortality. These results 
suggest that when a patient is on higher doses of opioids clinicians should be more 
cognizant of an increased risk of SI and SB, especially if a patient has one or more of the 
known risk factors.  
Pain and Suicidal Ideation and Behavior: Possible Mediators  
 There are a number of postulated mediators for suicide in patients with chronic 
pain. These include catastrophizing; burdensomeness/social isolation and mental defeat 
Catastrophizing  
 Patients with chronic pain tend to engage pain-related catastrophizing which can 
be conceptualized as magnified, exaggerated negative focus on pain that can contribute 
to depression and disability and in turn exacerbate an individual’s experience of pain and 
suffering.16 The association between SI and individual differences in the use of pain-
related coping strategies and pain catastrophizing was assessed in a large cohort of 
1,515 patients with chronic pain. In this sample, 32% reported recent SI. It was revealed 
that the extent of depression and pain catastrophizing best predicted the occurrence and 
the degree of SI. 4   
Burdensomeness and Social Isolation 
 A prevailing theory of SI and SB is based on the interpersonal theory of suicide by 
Joyner and colleagues.17 This theory proposes that thwarted belongingness (unfulfilled 
need for social interaction and connectedness), and perceived burdensomeness 
(perceiving oneself as a burden or a liability to others, particularly family members) are 
two primary factors that significantly contribute to the context that leads to SI and possible 
SB. These two factors are.  In a study by Kranzler et al,18 113 patients with chronic 
nonmalignant pain were evaluated and a logistic regression model revealed that one 
question measuring perceived burdensomeness was the only predictor of suicidal 
ideation. Cheatle et al3 also discovered that social withdrawal and isolation were 
predictive of SI in a cohort of 466 patients undergoing treatment at a pain center.  
 According to the interpersonal theory of suicide, the desire for suicide is caused by 
the confluence of thwarted belongingness and perceived burdensomeness and the 
capability for SB and attempts develop in response to repeated exposure to 
physically/emotionally painful and/or fear-inducing experiences. This is very pertinent to 
the patients with chronic pain, as two strong risk factors for suicide are pain duration and 
pain intensity.  
Mental Defeat 
 A novel construct for increased risk of suicidal ideation in chronic pain is mental 
defeat, which has been defined as a state of mind marked by a loss of autonomy, agency 
and human integrity.19-22  
 The link between mental defeat and suicide intent has been investigated in a 
recent study with 62 patients seeking specialist treatment from a hospital chronic pain 
self-management service.23 Among these patients, 22.6% had a history of past suicide 
attempts, with 69% indicating that their wish to die during the last attempt being moderate 
to high. All participants completed a set of questionnaires assessing factors that have 
been linked to suicidality. Two hierarchical linear regression analyses were subsequently 
carried out to examine the effect of mental defeat – in competition with the remaining 
significant correlates of suicidality (pain intensity, anxiety, depression and pain 
catastrophizing) – on worst-ever suicide intent, as measured with the 21-item Beck Scale 
of Suicide Ideation.24 Both regression models controlled for the effect of pain intensity 
(step 1), but in the first model mental defeat was entered to the equation first (step 2) 
before the three psychological predictors, namely anxiety, depression and pain 
catastrophizing (step 3), whereas in the second model, the entry order was reversed so 
that mental defeat (step 3) was added to a full model of pain intensity (step 1), anxiety, 
depression, and pain catastrophizing (step 2) last. As expected, pain intensity alone was 
a significant predictor of predictor of worst-ever suicide intent in both models. When 
mental defeat was added to the model next, it improved the predictor by increasing the 
total amount of variance explained from 11% to 23%. In contrast, the combined power of 
anxiety, depression and pain catastrophizing was weaker and did not significantly 
improve the model’s prediction of suicide intent. Also, none of the psychological predictors 
included in the model, except mental defeat, was found to be a significant predictor of 
suicide intent. These findings suggest that the effect of mental defeat on suicide intent is 
independent of pain intensity and that mental defeat may be a better predictor of suicide 
intent than anxiety, depression and pain catastrophizing, both as individual and as a 
combined set of predictors.  
Screening for Risk of Suicide  
 Screening for risk of suicide in patients with chronic pain should include general 
mental health screening, SUD screening, assessing sleep disturbance and specific tools 
to assess SI and SB.  
Mental Health Screening 
 There are a number of self-administered measures of depression for example the 
Beck Depression Inventory (BDI)24, Profile of Mood States (POMS)25, and Patient Health 
Questionnaire (PHQ-9).26 Two measures of anxiety that are highly valid and reliable are 
the Beck Anxiety Inventory (BAI)27 and the State-Trait Anxiety Inventory.28 There are also 
tools that assess both depression and anxiety such as the Hospital Anxiety and 
Depression Scale.29 
 Substance Use Disorder Assessment 
 While patients with pain have an elevated risk for SI, those patients with both pain 
and SUD are particularly vulnerable to the risk of SI and SB. Assessing the presence of 
a SUD, therefore, is critical in this patient population.  
 Examples of assessment tools for SUDs include the CAGE-AID (Cut down, 
Annoyed, Guilty, Eye-opener Tool)30 which assesses for both alcohol and drug abuse,; 
and the DAST (Drug Abuse Screening Test).31 
 Risk assessment tools for potential prescription opioid misuse and abuse include 
the Opioid Risk Tool (ORT) 32 and the Screener and Opioids Assessment for Patients 
with Pain (SOAPP). 33 These two instruments are examples of assessing risk for potential 
aberrant drug-related behavior (ADRB) prior to the initiation of long-term opioid therapy. 
Examples of assessment tools to monitor misuse once opioid treatment has been initiated 
include the Current Opioid Misuse Measure (COMM)34 and the Prescription Drug Use 
Questionnaire(PDUQ).35 A recently developed tool, the ORT-OUD, has been 
demonstrated to predict the risk of developing an opioid use disorder with good specificity 
and sensitively. 36  
Screening Tools for Sleep Disturbance 
 Measures for insomnia predominantly include patient self-report in questionnaire 
and daily sleep diary to capture the subjective experience of sleep disturbance, but may 
also include objective measures such as actigraphy and polysomnography to provide 
objective estimates of sleep patterns and for the assessment of possible concomitant 
sleep disorders (e.g., sleep apnea, restless leg syndrome/period limb movement disorder, 
narcolepsy etc.). Self-report measures assess different aspects of sleep disturbance. 
Moul et al provide a review of the various sleep assessment scales.37 
 
Screening Tools for Mental Defeat  
 The Pain Self Perception Scale (PSPS) has been developed to assess the sense 
of mental defeat in relation to pain experiences.19 The PSPS contains 24 items that 
describe negative thoughts and feelings people may have about themselves due to a 
specified recent episode of intense pain. All items begin with the referent “Because of the 
pain…”, followed by statements such as “…I felt defeated by life”,  “…I felt destroyed as 
a person.” Respondents rate the extent to which each item applied to their specified 
recent episode of pain on a 5-point scale (0-4), where 0 is anchored with “not at all/never” 
and 4 “very strongly”. Scores of each item are then summed to give a total score that 
ranges from 0-96, with higher scores indicating higher levels of mental defeat in relation 
to pain.  
Screening Tools for Suicide 
 The Columbia Suicide Severity Rating Scale (C-SSRS) has been frequently used 
for clinical trials on new medications and in clinical practice. The C-SSRS assesses a 
number of domains including ideation, intensity, behaviors, severity of self-injury and 
potential lethality of suicide attempts.38 The C-SSRS provides greater precision in the 
assessment of SB and SI but due to its length can be cumbersome with regards to clinical 
practice.  
 Another example of a commonly used assessment for risk of suicide is the Suicide 
Assessment Five-Step Evaluation and Triage (SAFE-T) assessment tool that was 
developed in collaboration with Substance Abuse and Mental Health Services 
Administration (SAMHSA).39 The SAFE-T includes assessment of risk factors such as 
suicidal behavior, current and past psychiatric disorders, family history, change in 
treatment and access to fire arms; protective factors, both internal, such as the ability to 
cope with stress, spiritual or religious beliefs and frustration tolerance, and external, such 
as responsibility to children or others and having a positive therapeutic relationship and 
good social supports; suicidal inquiry which asks specific questions about thoughts, plans, 
behaviors, intents, risk level and intervention; assesses the risk level based on the clinical 
judgment after completing the first three steps. Patients are stratified into low, moderate 
and high risk, with specific interventions indicated for each risk level.   
Prevention and Treatment Strategies  
Preventative Measures  
 Patients who present with moderate to severe depression with or without 
endorsing SI or plans should be co-managed with a behavioral health specialist. Patients 
who acknowledge active SI may require inpatient treatment depending on certain factors 
such as: depression and SI severity; if they have vague or specific plans for completing 
suicide including having access to means (potentially lethal medications or own a gun); 
history of past SB or impulsivity. During an acute phase the patient will require meaningful 
treatment both consisting of pharmacotherapy and intensive psychotherapy.  The 
pharmacotherapy strategy should include managing depressive symptomatology, sleep 
disturbance, and pain. If opioid or benzodiazepine use is necessary, these medications 
should be prescribed cautiously, in small amounts and held and administered by a family 
member. 10 
Interventions/Treatment  
 There are a number of pharmacologic and nonpharmacologic interventions to 
mitigate the risk of SI/SB.  
Pharmacologic Treatment to Manage SI/SB in Patients with Pain 
For suicidal patients with or without pain, the general pharmacological strategy is to 
treat comorbid illness that leads to increased suicide risk, including depression, anxiety, 
sleep disorder, psychosis, and uncontrolled pain.   
 Medications that show benefit for reducing suicidality 
Four medications have been shown to decrease risk of suicide: lithium, clozapine, and 
ketamine and buprenorphine. Lithium is a first line treatment for bipolar depression and 
also may be used to augment antidepressants in treatment resistant depression.  It has 
been shown to decrease suicidality in patients with mood disorders.40 Clozapine is an 
atypical antipsychotic frequently used for treatment resistant schizophrenia and 
schizoaffective disorders, and has also been shown to decrease suicides in these 
populations.41  Ketamine is a NMDA receptor antagonist that has recently been shown 
to have potent and rapid antidepressant and pain relieving effect.  In several small 
studies ketamine has shown promise in rapidly reducing SI.42 Most recently 
buprenorphine has shown promise in abating even acute SI.43  
 Medications that treat comorbid risk factors for suicidality: Depression, Sleep, 
and Anxiety 
Patients with pain often have comorbid anxiety, sleep and mood disturbance, which 
can increase risk of SI/SB.  Many of these comorbidities may be treated with 
antidepressants. Augmenting strategies including anxiolytics, sleep aids, and 
antiepileptics, may also be employed.  
a) Antidepressants 
 For suicidal patients with comorbid depression, anxiety and pain, treating with an 
antidepressant should be considered. There is no clear data showing that any single 
antidepressant works better than another, so the choice of antidepressant depends on 
the patient’s comorbidities, the side effect profile, and the whether the goal is to add 
additional pain control. Selective serotonin reuptake inhibitors (SSRIs) and 
serotonin/norepinephrine reuptake inhibitors (SNRIs) are first line agents for treating 
depression and anxiety disorders.  SSRIs may be better tolerated, while SNRIs also 
treat pain. For SNRIs and SSRIs, it is often good to start at a low dose, even half of the 
typical recommended starting dose, because initial side effects can include elevated 
anxiety, prompting anxious patients to discontinue the drug before it has a chance to 
take effect.   Other side effects can include sexual dysfunction, nausea and diarrhea, 
insomnia and weight gain. Of note, SSRIs and SNRIs, while effective for depression, 
anxiety and pain, have been shown to disrupt and fragment sleep. 44 
 Tricyclic antidepressants (TCAs) such as amitriptyline and doxepin are a good 
choice for patients with depression, anxiety, and sleep disorder, and also have benefit 
for pain.14 However, this benefit must be carefully weighed by their risk in suicidal 
patients, as they are extremely lethal in overdose. 45 Other significant side effects 





 Although many clinicians avoid benzodiazepines, a long acting benzodiazepine 
such as clonazepam can be useful in the short term to reduce anxious agitation in a 
suicidal patient, since such agitation potentially contributes to completed suicide. 46  
They ought not to be combined with opioids, and as with TCAs given in small or 
observed doses. Other medications potentially useful for anxiety include buspirone, 
hydroxyzine, and antiepileptic drugs.   
c) Anticonvulsants 
Like antidepressants, antiepileptics may be used to treat not just pain, but also anxiety 
and sleep disturbance.  Gabapentin and pregabalin both have some benefit for both 
sleep and anxiety. 47 
d) Sleep aids 
 As mentioned above, the tricyclic antidepressants can be effective for treating 
sleep.  Many patients may need additional assistance to fall asleep and stay asleep, so 
adding a dedicated sleep aid is an option. Eszopiclone not only treats sleep but also 
anxiety.  Trazodone is an antidepressant that at low doses is indicated for sleep.  
Mirtazepine similarly is an antidepressant that improves sleep.14  
 Special consideration: Risk of Suicidality with Antidepressants and 
Anticonvulsants 
 
 Antidepressants (of all classes) and antiepileptic drugs have the additional 
complication of possibly leading to SI/SB in some patients.  In 2004 the FDA issued a 
black box warning, regarding an increased risk of SI/SB in children and adolescents, 
which was extended to young adults (age 18-25) in 2006. 48 This warning was based on 
a meta-analysis showing approximately 2-fold increase in risk of SI/SB in these 
populations.  Of note, there were no completed suicides and no distinctions among 
class of antidepressant.  Antidepressants in older patients (age 65 and older) are 
actually protective against SI/SB.  A similar analysis of antiepileptic drugs showed an 
increased risk of SI/SB in patients with various disorders taking any antiepileptic drug, 
again showing approximately 2-fold increased risk in those taking anticonvulsants over 
placebo, with no distinction among age. 49 
 On balance, the risk of untreated depression on suicide in a general population 
outweighs the risk of treating with an antidepressant.48   
Behavioral Interventions 
 Cognitive Behavioral Therapy  
 CBT has been highly efficacious in treating mood and anxiety disorders and the 
basic principles of CBT have been applied to other conditions including pain, sleep and 
substance use disorders (SUD).  
a)  CBT-Pain 
 CBT can include various techniques to assist and support the patient in identifying 
maladaptive behaviors and/or dysfunctional thought patterns that may diminish the 
patient’s ability to adjust to and cope with their chronic pain thus contributing to their 
related depression and anxiety.  
 The process of CBT typically involves the patient acquiring specific skills which 
can include mindfulness-based stress reduction, progressive muscle relaxation training, 
pacing, effective communication, cognitive restructuring, which is followed by skill 
consolidation, rehearsal and relapse training.50  
 There is a robust literature supporting the clinical efficacy and cost-effectiveness 
of CBT in improving mood, anxiety and functionality in a number of chronic pain disorders.  
 CBT-Insomnia 
 CBT tailored to insomnia has also been effective in improving sleep disturbance. 
As noted above, sleep disturbance is highly prevalent in patients with chronic pain, pain 
and sleep are bidirectional and sleep disturbance is a known risk factor for SI/SB in 
patients with chronic nonmalignant pain.   
 There is evidence that CBT-Insomnia (CBT-I) in patients with chronic primary 
insomnia, is equally effective or even superior to pharmacotherapy in multiple 
outcomes. 51 
 A course of CBT-I typically includes:  psychoeducation about sleep and 
insomnia; stimulus control; sleep restriction; sleep hygiene; relaxation training; and 
cognitive restructuring.  
CBT, Pain and SUD 
 There is emerging evidence that CBT can reduce the risk of prescription opioid 
misuse and abuse in high-risk patients indirectly by improving mood, anxiety, sleep and 
pain coping skills and also in improving outcomes in patients with pain who have a history 
of a SUD. In a recently published pilot study,52 patients with Hepatitis C who also 
experienced chronic pain and had a history of SUD were enrolled in an 8-session 
integrated group CBT program for chronic pain and SUD. Results revealed improvement 
in key outcomes including pain-related interference, reduction in cravings for alcohol and 
other substances, and a decrease in past-month alcohol and substance use.  
Conclusions 
 Patients suffering from persistent pain often present with complicating medical and 
psychiatric comorbidities including mood and anxiety disorders and a substantial 
subgroup of this patient population experience SI and engage in SB.  A number of risk 
factors for SI/SB have been identified in the general population including gender, age, 
social isolation, past history of suicide attempts and several more specific to the pain 
population such as sleep disturbance, pain intensity and duration, and opioid dosing as 
well as potential mediators of pain and SI/SB such as burdensomeness, sleep 
disturbance and mental defeat. Many of these risk factors and mediators are modifiable 
thus reducing the potential of SI and SB in this vulnerable patient population. Clinicians 
need to be cognizant of the potential of SI/SB when managing patients with chronic 
nonmalignant pain, routinely screen for and treat or refer for treatment of concomitant 
mood, anxiety, sleep and substance use disorders and develop a plan of action if patients 
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Table 1. Risk Factors for Suicide 
 
 Gender (female)                                                         
 
 Age (> 45 years old) 
 
 Acute losses and stressors 
 
 Chronic medical illnesses 
 
 Previous suicide attempts 
 
 Concomitant mental health history  
       (especially depression and SUD) 
 
 Social isolation/poor social support 
 






 Frequency of Suicidal Ideation 
 
 Severity of psychiatric disease 
 
 Past psychiatric hospitalizations  
 
 Past suicide attempt 
 
 Pain Type * 
 
 Pain Intensity * 
 
 Pain Duration * 
 
 Sleep disturbance * 
 
 Opioid dosing * 
 
* pain specific risk factors 
